We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel Diagnostic Device Profiles Population of Gut Microbiome

By LabMedica International staff writers
Posted on 05 Aug 2019
Researchers used a three-dimensional (3D) printer to manufacture a novel pill-like diagnostic tool capable of profiling the bacterial species comprising the gut microbiome in the critical area between the stomach and the colon.

Investigators at Tufts University (Medford/Somerville, MA, USA) recently described a novel non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract. More...
The device was manufactured in a three-dimensional printer.

The surface of the pill was covered with a pH-sensitive coating, so that it did not absorb any substances until it passed through the stomach and entered the small intestine, where the coating dissolved. A semi-permeable membrane separated two chambers in the pill - one containing helical channels that captured bacteria and the other containing a calcium salt-filled chamber, which created an osmotic flow across the membrane that forced the bacteria into the helical channels. A small magnet in the pill enabled controlled movement and targeting via a magnet outside the body. Finally, a fluorescent dye in the salt chamber marked the pill for easy identification after it left the body.

The pill's sampling performance was characterized using realistic in vitro models and validated in vivo in pigs and primates. So far, results have indicated that the bacterial populations recovered from the pills’ microfluidic channels closely resembled the bacterial population demographics of the microenvironment to which the pill was exposed. Despite these promising results, clinical trials will be needed to determine if the pill can be adapted for routine use in humans.

"We are learning quite a lot about the role of gut microbiome in health and disease. However, we know very little about its biogeography," said senior author Dr. Sameer Sonkusale, professor of electrical and computer engineering at Tufts University. "The pill will improve our understanding of the role of spatial distribution in the microbiome profile to advance novel treatments and therapies for a number of diseases and conditions."

The microbiome profiler was described in the July 19, 2019, online edition of the journal Advanced Intelligent Systems.

Related Links:
Tufts University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.